Showing results (251-260 of 419) with videos related to

Sort By:
Pageof 42
Cancer Chemotherapy and Pharmacology|October 27, 2020
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysisSalvador Fudio, Josep Tabernero, Vivek Subbiah, et al.
Oncotarget|April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancerZhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
British Journal of Cancer|February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trialsShiraj Sen, Kenneth Hess, David S Hong, et al.
Molecular Cancer Therapeutics|February 8, 2022
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid TumorsMatteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, et al.
Oncotarget|March 3, 2016
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimusXiaochun Liu, Susan Kambrick, Siqing Fu, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 2026
Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapyMilan Radovich, James Wacker, Jeffrey Solzak, et al.
Cancer|July 15, 2016
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trialsGoldy C George, Eucharia C Iwuanyanwu, Karen O Anderson, et al.
Molecular Cancer|March 27, 2024
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE studyBlessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, et al.
Oncotarget|May 6, 2016
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experienceMing-Mo Hou, Zhijie Wang, Filip Janku, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2016
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancersMuhammad R Khawaja, Alpa M Nick, Vinu Madhusudanannair, et al.
Pageof 42